Abstract With improvements in survival among individuals diagnosed and treated for cancer there is an increasing recognition of the risk of long-term adverse effects of therapy. Second neoplasms represent one of the more serious late effects of treatment and are associated with a substantial level of morbidity and mortality. Survivors of childhood cancers, because of their potential longevity, are at particular risk for this adverse outcome. The Childhood Cancer Survivor Study is a large cohort consisting of adult survivors of childhood cancer diagnosed and treated between 1970 and 1986. The CCSS has provided important data to quantify radiation-associated risk for subsequent cancers including neoplasms of the breast, thyroid and central nervous system.
Introduction
The Office of Cancer Survivorship at the National Cancer Institute estimates that more than 11 million people in the U.S. are survivors of cancer. Among this large survivor population, nearly two-thirds are greater than 5 years beyond their cancer diagnosis. The increasing number of cancer survivors can be attributed to a number of factors, including more effective approaches to early detection and treatment.
During the last three to four decades the survival rates have increased markedly for many of the cancers diagnosed and treated during childhood and adolescence [1] . Recent data based on the U.S. population document 5-year survivorship of 79% for childhood cancer patients diagnosed from 1995 to 2001. Along with this success has come the realization that the therapies responsible for longterm survival of these patients also carry with them the potential for late-occurring adverse consequences. To varying degrees, it has been shown that long-term survivors are at risk of developing a spectrum of adverse outcomes including early death; second neoplasms; organ dysfunction such as cardiac, pulmonary, and endocrine; reduced growth and development; decreased fertility; impaired cognitive function; difficulties obtaining employment and insurance, and overall reduction in quality of life. Because of the young age at which these cancer patients are treated, and thus their potential longevity, the long-term effects of therapy are likely to have a much greater impact on their lives, families, and society at large, than the acute complications of therapy they have already endured.
Beginning in the mid-to late-1970s, reports from single institutions began documenting the potential risk of treatment-related late effects. Most of the earliest published reports reflect either case reports or case-series and are limited by a small sample size or were derived from patient populations treated in a similar fashion. Thus, accurate quantification of exposure-specific risk was generally not possible. However, these initial observations provided direction for future collaborative research. Summarized in this report are data from the Childhood Cancer Survivor Study (CCSS) that address the topic of treatment-related second neoplasms among long-term survivors, with specific emphasis on risks associated with radiation treatment exposures.
The childhood cancer survivor study
The CCSS is a resource supported by the National Cancer Institute consisting of a retrospective cohort of children and adolescents treated for childhood cancer at 26 collaborating institutions in the United States and Canada (see Appendix). Eligibility criteria for the cohort included: individuals diagnosed before age 21 years with leukemia, CNS cancers, Hodgkin disease, non-Hodgkin lymphoma, kidney cancers, neuroblastoma, soft-tissue sarcomas, and bone tumors, with initial treatment between Jan. 1, 1970, and Dec. 31, 1986 , and survival for at least 5 years from diagnosis. Details including characteristics of this cohort and the study design have been previously described [2] . Briefly, beginning in 1994 all participants (or parents of participants <18 years of age) completed a self-administered baseline questionnaire or telephone interview. Subsequent update questionnaires/interviews have been administered every 2-3 years (study surveys are available at www.stjude. org/ccss). Treatment information, including surgical procedures, chemotherapy, and radiation therapy, was abstracted from medical records using a structured protocol. Data collected also included the dates of initiation and cessation of treatment for all chemotherapeutic agents, cumulative doses and routes of administration for 28 specific agents, and all surgical procedures. Records from radiation oncology departments (including treatment positions and diagrams) were centrally reviewed at the CCSS Radiation Data Center at the University of Texas M.D. Anderson Cancer Center for dosimetry assessment.
Among the CCSS cohort, second and subsequent neoplasms were initially ascertained through self-report via study questionnaires. Survivors, or their surrogate respondents, were asked to report the occurrence of any cancer (either a relapse of the initial childhood cancer or a new cancer), the institution where the subsequent diagnosis was made, and the treating physician. All positive responses were screened by the co-chair of the Second Malignancies Working Group, and those responses representing likely or possible second neoplasms were validated with the pathology report. All pathology reports were centrally reviewed by the CCSS Pathology Center at the Cooperative Human Tissue Network in Columbus, OH. In the event that a pathology report could not be successfully obtained, the patient or surrogate response, death certificate, or other institutional records were reviewed to make a determination of whether the reported occurrence was a second neoplasm.
Quantification of risk of second neoplasms
Various metrics can and are often used to quantify risk of second and subsequent neoplasms. Cumulative incidence estimates are calculated using time from diagnosis or some subsequent time point (e.g., 5 years) after childhood cancer diagnosis to the occurrence of the second neoplasm, while treating death as a competing risk event and censoring at the date of last contact [3] . Person-years of follow-up are calculated as the minimum time to second malignancy, death or last contact. Standard errors of cumulative incidence estimates are calculated and used to evaluate 95% confidence intervals (CI) [4] . To quantify risk of second malignant neoplasms, the standardized incidence ratios (SIR) and excess absolute risk (EAR) are used. The SIR can only be calculated for diagnoses that are contained in the referent population cancer incidence data being utilized. Thus, in the U.S., non-melanoma skin cancers, most non-invasive cancer, and non-malignant tumors (i.e., those without an ICDO behavior code of 3) such as benign meningioma cannot be included in SIR or EAR calculations. Typically in the U.S., SIR of observed to expected malignancies are calculated using the surveillance, epidemiology, and end results (SEER) age-, sex-and race-specific incidence rates [5] . EAR is determined by subtracting the expected number of malignancies in the cohort from the observed number, dividing the difference by the person-years of follow-up, and multiplying by 1,000. In analyses to determine the relative risk (RR) of developing a second neoplasm, one typically estimates the risk for host characteristics of interest (e.g., age at diagnosis, sex, race/ethnicity, etc.), as well as therapeutic exposures (e.g., radiation dose/ site, chemotherapeutic agent, etc.) using a Poisson multivariable regression model with age as the timescale [6, 7] .
Overall risk of second neoplasms in the CCSS cohort
The initial assessment of second neoplasms in the CCSS cohort, published by Neglia et al. [8] , demonstrated a cumulative incidence of second neoplasms (excluding nonmelanoma skin cancers) of 3.2% at 20 years from original cancer diagnosis, which reflects a SIR of 6.38 (95% CI 5.67-7.13). The cumulative incidence, EAR, and SIR for second malignancies within specific diagnostic groups of childhood cancers are summarized (Fig. 1) . Multivariate analyses, adjusting for any exposure to therapeutic doses of radiation, demonstrated that risk of a second neoplasm was significantly associated with female sex (P<0.001), childhood cancer diagnosed at a younger age (P<0.001), initial cancer diagnosis of Hodgkin disease (P<0.001) or softtissue sarcoma (P=0.01), and exposure to alkylating agent chemotherapy (P=0.02).
Assessment of risk according to type of second cancer demonstrated that the highest risks were seen for secondary tumors involving bone, breast, thyroid and central nervous system (Fig. 2) . Based on these results, CCSS investigators initiated more in-depth studies of secondary tumors including those of the breast, thyroid and central nervous system to further quantify risk associated with radiation therapy and other factors.
Radiation-associated thyroid cancer
Utilizing a nested case-control study design, CCSS investigated risk factors associated with the occurrence of a subsequent thyroid cancer [9] . The case series was derived from 72 pathologically confirmed cases of thyroid cancer (78% papillary, 15% follicular, 7% other/unspecified). The control series consisted of survivors free of thyroid cancer and with an intact thyroid gland. A stratified random selection procedure considering sex, age at diagnosis of initial cancer, and follow-up interval was applied using a case-to-control ratio of 1:4. A minimum latency period of 5 years was applied for calculation of radiation exposure to the thyroid gland, with separate doses calculated for the left and right lobes of the thyroid, as well as the pituitary gland. Doses absorbed by organs, including both those within the radiation therapy field and those resulting from scatter, were calculated. Any radiation exposure to the thyroid gland (versus no exposure) was associated with a 2.6-fold increased risk of subsequent thyroid cancer (95% CI 1.1-7.1). Observed risk of subsequent thyroid malignancy was dependent on estimated radiation dose to the thyroid, but not in a linear dose-dependent fashion (Fig. 3) . Rather, the risk pattern fit a linear exponential dose-response model, consistent with the cell-killing hypothesis. In this analysis, radiation doses above 30 Gy to the thyroid gland were associated with a diminished risk of subsequent thyroid cancer compared to lower doses of radiation. While radia- tion exposure was the main focus of the nested case-control study, it is noteworthy that no statistically significant associations were identified with exposure to chemotherapeutic agents.
Radiation-associated breast cancer
During the last 15 years numerous published reports have documented an excess occurrence of breast cancer among young women treated with chest radiation during the pediatric or adolescent time period [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . As described above, this excess risk has been documented within the CCSS cohort. Because of the characteristics of the CCSS, it has been possible to further investigate the magnitude of the long-term risk and to gain a greater understanding of the potential modifiers of risk.
An analysis of the 6,068 women in the CCSS cohort focused on identification of risk factors for breast cancer [24] . A total of 111 confirmed cases of breast cancer, among 95 survivors, were included in the assessment of potential risk factors including primary cancer diagnosis, radiation and chemotherapy, age at diagnosis of initial childhood cancer, follow-up time since initial diagnosis, menstrual and reproductive history, and family history of cancer. The median age at diagnosis of breast cancer was 35 years (range 20-49 years), with a median interval between initial cancer diagnosis and breast cancer of 19 years (range 6-29 years). Among the survivors diagnosed with a subsequent breast cancer, the most common initial cancer diagnosis was Hodgkin disease (68%), followed by bone sarcoma (9%), and soft-tissue sarcoma (8%). Seventy-eight percent of survivors with breast cancer had received radiation therapy involving the chest, compared with only 20% of female survivors who had not developed breast cancer.
Risk of breast cancer among female survivors, relative to expected rates within the general population, are presented in Table 1 . Statistically significantly elevated standardized incidence ratios were observed among those exposed to chest radiation for all initial diagnoses combined, Hodgkin disease, bone and soft-tissue sarcoma, non-Hodgkin lymphoma, and Wilms tumor. The highest excess was seen among survivors of Hodgkin disease following chest radiation, where the cumulative incidence of breast cancer was estimated to be 12.9% at 40 years of age. For survivors without radiation exposure to the chest, the incidence of breast cancer was highest among survivors of soft-tissue sarcoma (3.3% at 40 years of age).
Investigation of modifying factors, after adjustment for radiation exposure to the chest, identified family history of breast cancer and history of thyroid disease to infer an increased risk for breast cancer. Pelvic radiation exposure was found to be independently associated with a statistically significantly decreased risk of breast cancer.
Radiation-associated CNS tumors
Employing a nested case-control study design, CCSS investigators evaluated risk factors for the occurrence of new primary neoplasms of the central nervous system, with a specific interest in a dose-response pattern of radiation exposure [25] . This report included assessment of 116 survivors who developed a subsequent CNS tumor, each compared to four individually matched control subjects (matched on age at original cancer diagnosis and sex). The median interval between original cancer diagnosis and development of a subsequent glioma or subsequent meningioma was 9 and 17 years, respectively. Radiation exposure was statistically significantly associated with risk of a subsequent CNS tumor (OR=6.8 for glioma and OR=9.9 for meningioma), with a linear dose-response pattern. However, the pattern differed substantially for glioma compared to meningioma, with slopes of 0.33 and 1.06 per Gy, respectively. Younger age at radiation exposure was an independent risk factor for a secondary glioma.
Conclusion
While the body of literature documenting the increased risk of second and subsequent cancers among pediatric cancer survivors is substantial, there still remain many unknowns about the very long-term effects (Fig. 4) . Ongoing surveillance will, with time, provide answers to these important questions: (1) to what degree will cancer treatment exposures in childhood impact upon an earlier onset of adult malignancies? and (2) how many new Table 1 Standardized incidence ratios (SIR) and 95% confidence intervals for breast cancer among childhood cancer survivors exposed and not exposed to chest radiation (adapted from Kenney et al., [24] In looking forward, it is clear that efforts are being made, where possible, to limit exposure to radiation and chemotherapy in pediatric cancer populations. Moreover, with the continuing technological advances new options are available to reduce exposures to non-cancer tissues, with the anticipated result being a reduction in long-term iatrogenic risks. Rigorous, systematic study of exposed populations will be required to document the impact of these efforts, as well as the investigation of risk factors that operate either independently or through interaction to modify risk of radiation-associated late effects.
